BioNexus Gene Lab (BGLC)

Chemrex is the group’s established commercial operation. It distributes chemical raw materials used in industrial applications, with a focus on customers in Southeast Asia. This business connects manufacturers and other industrial buyers with input materials needed for production processes, making it dependent on supply chain reliability, customer relationships, pricing conditions and regional manufacturing activity. The industrial chemicals segment represents the company’s more traditional revenue base.

MRNA Scientific gives BioNexus exposure to the healthcare diagnostics market. The subsidiary develops and provides blood-based genomic screening services designed to support early disease risk assessment and health management. These services sit within a broader global trend toward preventive healthcare, molecular diagnostics and personalised medicine, where genetic and blood-based testing can help identify potential health risks before symptoms become advanced. Commercial success in this area depends on clinical utility, regulatory compliance, market adoption and the ability to build trust among healthcare providers and consumers.

BioNexus reports its activities across industrial chemical trading, genomic screening services and investment holding. That mix makes the company unusual among small listed businesses, as it pairs a conventional distribution model with a biotechnology-oriented diagnostics platform. Investors evaluating BioNexus typically consider both the stability and margins of the chemicals business and the longer-term potential, execution risk and regulatory demands associated with commercialising proprietary genomic screening services.